Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma

Ana Markovic, Christine H. Chung

Research output: Contribution to journalArticle

Abstract

New agents and treatment strategies that can be safely and effectively integrated into current treatment paradigms for head and neck squamous cell carcinoma (HNSCC) are urgently needed. To date, the anti-EGF receptor (EGFR) monoclonal antibody, cetuximab, is the first and only molecularly targeted therapy to demonstrate a survival benefit for patients with recurrent or metastatic disease. Other anti-EGFR-targeted therapies, including monoclonal antibodies (e.g., panitumumab and zalutumumab) and reversible and irreversible ErbB family tyrosine kinase inhibitors (e.g., lapatinib, afatinib and dacomitinib) are being actively investigated in Phase II and Phase III clinical trials. In addition, validated biomarkers are needed to predict clinical benefit and resistance to anti-EGFR therapy in HNSCC. This review will compare and contrast the mechanisms of action of anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors and also discuss their role in the management of HNSCC and the potential impact of human papillomavirus status in the development of these targeted agents.

Original languageEnglish (US)
Pages (from-to)1149-1159
Number of pages11
JournalExpert Review of Anticancer Therapy
Volume12
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Monoclonal Antibodies
Therapeutics
Phase III Clinical Trials
Biomarkers
Carcinoma, squamous cell of head and neck
Survival

Keywords

  • epidermal growth factor receptor
  • head and neck squamous cell carcinoma
  • HER tyrosine kinase receptor family
  • therapeutic monoclonal antibody
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma. / Markovic, Ana; Chung, Christine H.

In: Expert Review of Anticancer Therapy, Vol. 12, No. 9, 09.2012, p. 1149-1159.

Research output: Contribution to journalArticle

@article{8c3dd5f62c1a42a188b57a6f4eddaeee,
title = "Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma",
abstract = "New agents and treatment strategies that can be safely and effectively integrated into current treatment paradigms for head and neck squamous cell carcinoma (HNSCC) are urgently needed. To date, the anti-EGF receptor (EGFR) monoclonal antibody, cetuximab, is the first and only molecularly targeted therapy to demonstrate a survival benefit for patients with recurrent or metastatic disease. Other anti-EGFR-targeted therapies, including monoclonal antibodies (e.g., panitumumab and zalutumumab) and reversible and irreversible ErbB family tyrosine kinase inhibitors (e.g., lapatinib, afatinib and dacomitinib) are being actively investigated in Phase II and Phase III clinical trials. In addition, validated biomarkers are needed to predict clinical benefit and resistance to anti-EGFR therapy in HNSCC. This review will compare and contrast the mechanisms of action of anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors and also discuss their role in the management of HNSCC and the potential impact of human papillomavirus status in the development of these targeted agents.",
keywords = "epidermal growth factor receptor, head and neck squamous cell carcinoma, HER tyrosine kinase receptor family, therapeutic monoclonal antibody, tyrosine kinase inhibitor",
author = "Ana Markovic and Chung, {Christine H.}",
year = "2012",
month = "9",
doi = "10.1586/era.12.91",
language = "English (US)",
volume = "12",
pages = "1149--1159",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "9",

}

TY - JOUR

T1 - Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma

AU - Markovic, Ana

AU - Chung, Christine H.

PY - 2012/9

Y1 - 2012/9

N2 - New agents and treatment strategies that can be safely and effectively integrated into current treatment paradigms for head and neck squamous cell carcinoma (HNSCC) are urgently needed. To date, the anti-EGF receptor (EGFR) monoclonal antibody, cetuximab, is the first and only molecularly targeted therapy to demonstrate a survival benefit for patients with recurrent or metastatic disease. Other anti-EGFR-targeted therapies, including monoclonal antibodies (e.g., panitumumab and zalutumumab) and reversible and irreversible ErbB family tyrosine kinase inhibitors (e.g., lapatinib, afatinib and dacomitinib) are being actively investigated in Phase II and Phase III clinical trials. In addition, validated biomarkers are needed to predict clinical benefit and resistance to anti-EGFR therapy in HNSCC. This review will compare and contrast the mechanisms of action of anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors and also discuss their role in the management of HNSCC and the potential impact of human papillomavirus status in the development of these targeted agents.

AB - New agents and treatment strategies that can be safely and effectively integrated into current treatment paradigms for head and neck squamous cell carcinoma (HNSCC) are urgently needed. To date, the anti-EGF receptor (EGFR) monoclonal antibody, cetuximab, is the first and only molecularly targeted therapy to demonstrate a survival benefit for patients with recurrent or metastatic disease. Other anti-EGFR-targeted therapies, including monoclonal antibodies (e.g., panitumumab and zalutumumab) and reversible and irreversible ErbB family tyrosine kinase inhibitors (e.g., lapatinib, afatinib and dacomitinib) are being actively investigated in Phase II and Phase III clinical trials. In addition, validated biomarkers are needed to predict clinical benefit and resistance to anti-EGFR therapy in HNSCC. This review will compare and contrast the mechanisms of action of anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors and also discuss their role in the management of HNSCC and the potential impact of human papillomavirus status in the development of these targeted agents.

KW - epidermal growth factor receptor

KW - head and neck squamous cell carcinoma

KW - HER tyrosine kinase receptor family

KW - therapeutic monoclonal antibody

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84867950688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867950688&partnerID=8YFLogxK

U2 - 10.1586/era.12.91

DO - 10.1586/era.12.91

M3 - Article

C2 - 23098115

AN - SCOPUS:84867950688

VL - 12

SP - 1149

EP - 1159

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 9

ER -